Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Debt to Equity (2016)

Gyre Therapeutics (GYRE) has disclosed Debt to Equity for 7 consecutive years, with $0.0 as the latest value for Q3 2016.

  • On a quarterly basis, Debt to Equity fell 92.35% to $0.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $0.0, a 92.35% decrease, with the full-year FY2015 number at $0.04, changed N/A from a year prior.
  • Debt to Equity was $0.0 for Q3 2016 at Gyre Therapeutics, down from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.04 in Q4 2015 to a low of -$0.02 in Q4 2012.
  • A 5-year average of $0.01 and a median of $0.01 in 2014 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: plummeted 214.97% in 2012, then surged 341.03% in 2015.
  • Gyre Therapeutics' Debt to Equity stood at -$0.02 in 2012, then soared by 48.19% to -$0.01 in 2013, then skyrocketed by 138.39% to $0.0 in 2014, then surged by 768.93% to $0.04 in 2015, then tumbled by 96.12% to $0.0 in 2016.
  • Per Business Quant, the three most recent readings for GYRE's Debt to Equity are $0.0 (Q3 2016), $0.01 (Q2 2016), and $0.01 (Q1 2016).